NATCO Pharma (NATCOPHARM) Fundamentals 2026 — P/E 11.8x, Revenue Analysis | SniperIQ
NATCO Pharma (NATCOPHARM) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹16,742 Crore, trading at ₹934.80 on the BSE. This SniperIQ fundamentals page covers NATCO Pharma's valuation (P/E 11.8x, P/B 1.8x), profitability (net margin 34.8%), revenue (₹4,078 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is NATCO Pharma's market cap?
NATCO Pharma (NATCOPHARM) has a market capitalization of approximately ₹16,742 Crore, trading at ₹934.80 on the BSE. Market cap moves with the live share price.
What is NATCO Pharma's P/E ratio?
NATCO Pharma's trailing twelve-month P/E ratio is 11.8x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is NATCO Pharma?
NATCO Pharma runs a net profit margin of 34.8%, a gross margin of 83.1%, and an operating margin of 30.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does NATCO Pharma generate?
NATCO Pharma reported revenue of ₹4,078 Crore for fiscal year 2026, with net income of ₹1,419 Crore and earnings per share (EPS) of 79.21. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does NATCO Pharma pay a dividend?
NATCO Pharma offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is NATCO Pharma financially healthy?
NATCO Pharma carries a debt-to-equity ratio of 0.08x and a current ratio of 3.01x, with a market beta of 0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is NATCO Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For NATCO Pharma (NATCOPHARM) the key facts are: market cap ₹16,742 Crore, P/E 11.8x, revenue ₹4,078 Crore, 52-week range 660.05-1340.45. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track NATCO Pharma's full fundamentals live
Get NATCO Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.